Last reviewed · How we verify
HL-085
At a glance
| Generic name | HL-085 |
|---|---|
| Also known as | No other interventions |
| Sponsor | Shanghai Kechow Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors (PHASE2)
- Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study (PHASE2)
- HL-085 in NRAS-mutated Advanced Melanoma (PHASE2)
- Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) (PHASE2)
- HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation (PHASE2)
- A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation (PHASE1)
- Study of HL-085 in NRAS Mutant Advanced Melanoma (PHASE1, PHASE2)
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL-085 CI brief — competitive landscape report
- HL-085 updates RSS · CI watch RSS
- Shanghai Kechow Pharma, Inc. portfolio CI